Literature DB >> 29906615

Studying a Rare Disease Using Multi-Institutional Research Collaborations vs Big Data: Where Lies the Truth?

Aileen C Johnson1, Cecilia G Ethun1, Yuan Liu2, Alexandra G Lopez-Aguiar1, Thuy B Tran3, George Poultsides3, Valerie Grignol4, J Harrison Howard4, Meena Bedi5, T Clark Gamblin6, Jennifer Tseng7, Kevin K Roggin7, Konstantinos Chouliaras8, Konstantinos Votanopoulos8, Darren Cullinan9, Ryan C Fields9, Keith A Delman1, William C Wood1, Kenneth Cardona1, Shishir K Maithel10.   

Abstract

BACKGROUND: Multi-institutional collaborations provide granularity lacking in epidemiologic data sets to enable in-depth study of rare diseases. For patients with superficial, high-grade soft tissue sarcomas of the trunk and extremity, the value of radiation therapy (RT) is not clear. We aimed to use the 7-institution US Sarcoma Collaborative (USSC) and the National Cancer Database (NCDB) to investigate this issue. STUDY
DESIGN: All adult patients with superficial truncal and extremity high-grade soft tissue sarcomas who underwent primary curative-intent resection from 2000 to 2016 at USSC institutions or were included in the NCDB from 2004 to 2013 were analyzed. Propensity score matching was performed. End points were locoregional recurrence-free survival (LRFS), overall survival (OS), and disease-specific survival (DSS).
RESULTS: Of 4,153 patients in the USSC, 169 patients with superficial high-grade tumors underwent primary curative-intent resection, 38% of which received RT. On multivariable Cox-regression analysis, RT was not associated with improved LRFS (p = 0.56), OS (p = 0.31), or DSS (p = 0.20). On analysis of 51 propensity score-matched pairs, RT was still not associated with increased LRFS, OS, or DSS. Analysis of 631 propensity score-matched pairs in the NCDB demonstrated improved 5-year OS rate associated with RT (80% vs 70%; p = 0.02). The LRFS and DSS rates were not evaluable.
CONCLUSIONS: Granular data afforded by collaborative research enables in-depth analysis of patient outcomes. The NCDB, although powered with large numbers, cannot assess many relevant outcomes (eg recurrence, DSS, or complications). In this study, the approaches yielded conflicting results. The USSC data suggested no value of radiation and the NCDB demonstrated improved OS, contradicting all randomized controlled trials in sarcoma. The pros and cons of either approach must be considered when applying results to clinical practice, and underscore the importance of randomized controlled trials.
Copyright © 2018 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29906615     DOI: 10.1016/j.jamcollsurg.2018.05.009

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  5 in total

1.  Primary Gallbladder Neuroendocrine Tumors: Insights into a Rare Histology Using a Large National Database.

Authors:  Reed I Ayabe; Michael Wach; Samantha Ruff; Sean Martin; Laurence Diggs; Timothy Wiemken; Leslie Hinyard; Jeremy L Davis; Carrie Luu; Jonathan M Hernandez
Journal:  Ann Surg Oncol       Date:  2019-05-17       Impact factor: 5.344

Review 2.  The opportunities and shortcomings of using big data and national databases for sarcoma research.

Authors:  Heather G Lyu; Adil H Haider; Adam B Landman; Chandrajit P Raut
Journal:  Cancer       Date:  2019-05-15       Impact factor: 6.860

3.  Treatment Outcomes for Primary Hepatic Angiosarcoma: National Cancer Database Analysis 2004-2014.

Authors:  Ankit Mangla; Gino Cioffi; Jill S Barnholtz-Sloan; Richard T Lee
Journal:  Curr Oncol       Date:  2022-05-17       Impact factor: 3.109

4.  Retroperitoneal sarcoma perioperative risk stratification: A United States Sarcoma Collaborative evaluation of the ACS-NSQIP risk calculator.

Authors:  Patrick B Schwartz; Christopher C Stahl; Cecilia Ethun; Nicholas Marka; George A Poultsides; Kevin K Roggin; Ryan C Fields; John H Howard; Callisia N Clarke; Konstantinos I Votanopoulos; Kenneth Cardona; Daniel E Abbott
Journal:  J Surg Oncol       Date:  2020-06-17       Impact factor: 3.454

5.  Demographics, Changes in Treatment Patterns, and Outcomes of Bone and Soft Tissue Sarcomas in Korea-A Sarcoma-Specific, Institutional Registry-Based Analysis.

Authors:  Hyehyun Jeong; Hyeon-Su Im; Jeong Eun Kim; Jin-Hee Ahn; Wanlim Kim; Jong-Seok Lee; Si Yeol Song; Joon Seon Song; Kyung-Ja Cho; Hye Won Chung; Min Hee Lee
Journal:  Cancer Manag Res       Date:  2021-11-24       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.